▶️ Watch the press conference by Commissioner @SKyriakidesEU on vaccine deliveries and on the export transparency scheme. #StrongerTogether https://t.co/iczvKiAiRm — European Commission 🇪🇺 (@EU_Commission) January 25, 2021 Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than […]
Read More
Commission concludes exploratory talks with Valneva to secure a new potential vaccine
The European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19. The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses. This finalisation […]
Read More
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human […]
Read More
European Commission authorises second safe and effective vaccine against COVID-19
The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed […]
Read More
Affordable, accessible and safe medicines for all: the Commission presents a Pharmaceutical Strategy for Europe
The Commission has adopted a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU’s pharmaceutical industry. Europe’s Pharmaceutical Strategy has four main objectives: Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. in the […]
Read More
Commission approves contract with Moderna to ensure access to a potential vaccine
The European Commission approved a sixth contract under the EU Vaccines Strategy, this time with the pharmaceutical company Moderna. The contract provides for the initial purchase of 80 million doses on behalf of all EU Member States, plus an option to request up to a further 80 million doses, to be supplied once a vaccine […]
Read MoreCommission lists key steps for effective vaccination strategies and vaccines deployment
As Europe learns to live with the pandemic, the development and swift global deployment of safe and effective vaccines against COVID-19 remains an essential element in the eventual solution to the public health crisis. In this context, the Commission is working to ensure that there will be access to safe vaccines across Europe, and encourages […]
Read More
Remdesivir: European Commission guarantees access
On 28th July the European Commission signed a contract with the pharmaceutical company Gilead to guarantee treatment doses of Veklury, which is the trade name of remdesivir. Veklury was the first drug authorised on an EU level for the treatment of COVID-19. From early August, batches of Veklury will be made available to Member States […]
Read MoreCovid-19: Support for vaccine research with additional €100 million
The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership created in 2017 to develop vaccines to prevent future epidemics, has launched a call to support the rapid development and global manufacture of COVID-19 vaccines. The EU will co-fund the call with €100 million. The EU support is part of the pledge to invest €1 billion from Horizon […]
Read More